Navigation Links
Gallus BioPharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann-Pick Type B Disease
Date:7/31/2013

St. Louis, Missouri (PRWEB) July 31, 2013

Gallus Biopharmaceuticals, LLC (Gallus) has signed a development and manufacturing supply agreement with Genzyme, a Sanofi Company the pioneer in the development and delivery of transformative therapies for patients with rare and special unmet medical needs for over 30 years. As part of the multi-year agreement Gallus will provide process and method development, scale-up, clinical supply and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B. "Gallus is delighted to partner with Genzyme in bringing this therapy to patients in need," said Mark Bamforth, Gallus’ CEO and President. "We are confident that our deep process development expertise and over ten years of commercial, perfusion-based biomanufacturing for global markets using proprietary, flexible stainless steel bioreactors will result in successful delivery of this therapeutic molecule to advance Genzyme’s clinical program."

Niemann-Pick type B is caused by a deficiency of an enzyme called acid sphingomyelinase, which is required for the normal turnover of sphingomyelin, a major lipid of cell membranes. The enzyme deficiency causes sphingomyelin to accumulate in patients and leads to enlargement of the liver and spleen, lung disease, low blood cell counts and in some cases a shortened lifespan.

About Gallus BioPharmaceuticals

Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Missouri, was established in 2010 and acquired a world class commercial biopharmaceutical manufacturing facility from Johnson & Johnson’s Centocor division in 2011 and has grown its workforce by over 50% since then. In addition to process development and clinical supply services, Gallus currently produces two commercial products that a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
2. PolyTherics and Antitope Combine to Create Leading Provider of Solutions to Enable the Development of Better Biopharmaceuticals
3. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
4. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
5. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
6. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
7. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
10. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
11. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... April 20, 2015 Sinovac Biotech Ltd. (Nasdaq: ... today announced its unaudited financial results for the fourth ... Fourth Quarter 2014 Financial Highlights(Compared to the fourth ... million, a decrease of 11.4% from $22.9 million in ... stockpiling of H5N1 pandemic influenza vaccine of $0.1 million ...
(Date:4/17/2015)... , April 17, 2015  Centrillion Technologies, ... SBIR grant from the National Human Genome ... of Health (NIH). The grant will help ... the development of breakthrough genomic technologies, including ... fabricated substrates. Centrillion has been developing this ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery ... a Memorandum of Understanding with the Feinstein Institute ... New York to collaborate with the ... The collaboration brings together the drug ... clinical expertise of the Feinstein Institute in neurosciences ...
(Date:4/16/2015)... OSAKA, Japan , April 16, ... (CiRA) of Kyoto University and Takeda Pharmaceutical Company ... together to develop clinical applications of induced pluripotent ... diabetes mellitus, neurological disorders and cancer immunotherapy. The ... is designed to expedite multiple research projects for ...
Breaking Biology Technology:Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3
... Trial Data at the American Heart Association Late Breaker Session ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
... Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... , WEST LAFAYETTE, Ind. - Researchers have demonstrated ... called single-wall carbon nanotubes, possibly hastening their use ... electronics that are faster and consume less power ... used to revolutionize electronics by replacing conventional silicon ...
Cached Biology Technology:Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 2Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 3Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 4Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 5Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 6Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 7Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 8Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 9Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session 10Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 2Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 3Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 4Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 5Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 6Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 7Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 8Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany 9Imaging tool may aid nanoelectronics by screening tiny tubes 2Imaging tool may aid nanoelectronics by screening tiny tubes 3
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... the "Global Gesture Recognition Market in Automotive Sector ... analysts forecast the Global Gesture Recognition market in Automotive ... the period 2013-2018. Gesture recognition is the ... different gestures of an individual. Gesture recognition technology can ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/24/2015)... 2015   NexID Biometrics LLC, whose spoof-mitigation ... today announced the beginning of shipments of version 2.0 ... The company, based in Potsdam, N.Y. ... Expo, which began here today at the Walter E. ... of its SDK boosts the accuracy rate range to ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... survival and that of most other animals on earth. It ... discretely embedded into our everyday lives. Plants provide us with ... spite of their importance, very few of us could name ... us. True, most would have little difficulty in distinguishing between ...
... the Conservation Reserve Program (CRP) in the United States ... Questions abound regarding the fate of carbon sequestered in ... if the land is converted to grain crop production ... conserve the sequestered soil organic carbon (SOC). The effect ...
... 2009) - Researchers of the Michael G. DeGroote Institute ... that bacteria evolve into something that can make you ... issue of the Proceedings of the National Academy ... and assign risk to emerging diseases in the environment. ...
Cached Biology News:Will large amounts of soil carbon be released if grasslands are converted to energy crops? 2McMaster researchers discover new mode of how diseases evolve 2
... premium quality recombinant form of Thermus aquaticus ... for a wide range of PCR applications. ... performance, each preparation is extensively tested in ... DNA Polymerase possesses an integral 5′→3′ exonuclease ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Mouse polyclonal antibody raised against a partial recombinant NCLN. NCBI Entrez Gene ID = 56926...
Mouse monoclonal antibody raised against a partial recombinant FBXO11. NCBI Entrez Gene ID = FBXO11...
Biology Products: